/stocks — the workspaceLOADING
Alto Neuroscience, Inc. (ANRO) is a pharmaceutical preparations company. 7 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-11 from ANRO's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind ANRO’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from ANRO’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
A plain-English read on ANRO plus an auto-SWOT — built from ANRO's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate ANRO using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Has ANRO been issuing shares? Offering history →
Projected from ANRO's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentANRO files or announces.
ANRO has sold off after 5 of its last 8 earnings reports.
Each figure is one earnings reaction — how much ANRO moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Earnings reactions have been moderate.
ANRO has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+5.0% and -15.3%).
A more typical earnings reaction has been approximately ±4.6%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-07-13 | +5.0% |
| 2026-05-13 | -4.2% |
| 2026-03-16 | +0.4% |
| 2025-11-12 | -15.3% |
| 2025-08-13 | -1.9% |
| 2025-05-14 | +2.5% |
| 2025-03-20 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -5.4% |
| 2025-02-03 | -6.8% |
Total return including reinvested dividends, from ANRO’s adjusted closing prices. Past return is not a forecast and not investment advice.